LABORATORY CORP OF AMERICA HOLDINGS Form 10-Q May 04, 2006

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

(Mark One) þ	ne)									
	For the quarte	rly period ended March 31, 2006								
	OR									
	ION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF									
	For the trans	sition period from to								
	Commission file number <u>1-11353</u>									
		Y CORPORATION OF CA HOLDINGS								
	(Exact name of regist	rant as specified in its charter)								
	Delaware	13-3757370								
(State	e or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)								
	358 South Main Street, Burlington, North Carolina	27215								
	(Address of principal executive offices)	(Zip Code)								

(Registrant's telephone number, including area code) (336) 229-1127

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes **b** No "

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated file. See definition of "accelerated filer" and "large accelerated filer" in Rule 12b-2 of the Exchange Act. Large accelerated filer [°] Non-accelerated filer [°]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act. Yes "No b

Edgar Filing: LABORATORY CORP OF AMERICA HOLDINGS - Form 10-Q

The number of shares outstanding of the issuer's common stock is 124.7 million shares, net of treasury stock as of May 1, 2006.

INDEX

PART I. FINANCIAL INFORMATION

Item 1 Financial Statements:

Condensed Consolidated Balance Sheets March 31, 2006 and December 31, 2005

Condensed Consolidated Statements of Operations Three months ended March 31, 2006 and 2005

Condensed Consolidated Statements of Changes in Shareholders Equity Three months ended March 31, 2006 and 2005

Condensed Consolidated Statements of Cash Flows Three months ended March 31, 2006 and 2005

Notes to Unaudited Condensed Consolidated Financial Statements

- Item 2 <u>Management s Discussion and Analysis of</u> <u>Financial</u> <u>Condition and Results of Operations</u>
- Item 3 Quantitative and Qualitative Disclosures about Market Risk
- Item 4 Controls and Procedures

PART II. OTHER INFORMATION

- Item 1 Legal Proceedings
- Item 1A Risk Factors
- Item 2 Changes in Securities, Use of Proceeds and Issuer Purchases of Equity Securities

Item 6	<u>Exhibits</u>		
2			

PART I FINANCIAL INFORMATION

Item 1. Financial Statements

LABORATORY CORPORATION OF AMERICA HOLDINGS AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (in millions) (unaudited)

	March 31, 2006	December 31, 2005
ASSETS		
Current assets:		
Cash and cash equivalents	\$ 25.2	\$ 45.4
Short-term investments	46.2	17.7
Accounts receivable, net	522.2	493.4
Supplies inventories	59.8	65.4
Prepaid expenses and other	34.7	37.2
Deferred income taxes	39.4	43.2
Total current assets	727.5	702.3
Property, plant and equipment, net	376.4	381.5
Goodwill, net	1,476.2	1,477.0
Intangible assets, net	634.1	645.7
Investments in joint venture partnerships	580.3	578.9
Other assets, net	90.3	90.4
Total assets	\$ 3,884.8	\$ 3,875.8
LIABILITIES AND SHAREHOLDERS' EQUITY		
Current liabilities:		
Accounts payable	\$ 108.5	\$ 116.2
Accrued expenses and other	265.3	227.3
Short term borrowings and current portion of long-term debt	547.4	544.6
Total current liabilities	921.2	888.1
Long-term debt, less current portion	604.2	604.5
Deferred income taxes	401.7	408.9
Other liabilities	88.7	88.6
Total liabilities	2,015.8	1,990.1
Commitments and contingent liabilities		
Shareholders' equity: Common stock, 124.7 and 126.5 shares outstanding at		
March 31, 2006 and December 31, 2005, respectively	14.6	14.8
Additional paid-in capital	1,219.5	1,339.7
Retained earnings	1,438.2	1,336.3
Less common stock held in treasury	(891.7)	(888.5)
Unearned restricted stock compensation	·	(6.9)
Accumulated other comprehensive earnings	88.4	90.3
Total shareholders' equity	1,869.0	1,885.7

Edgar Filing: LABORATORY CORP OF AMERICA HOLDINGS - Form 10-Q

	March 31,	December 31,
Total liabilities and shareholders' equity	\$ 3,884.8	\$ 3,875.8

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

3

LABORATORY CORPORATION OF AMERICA HOLDINGS AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (in millions, except per share data)

(unaudited)

	Three Months Ended March 31,					
	2006	2005				
Net sales Cost of sales	\$ 878.5 505.8	\$ 799.1 460.8				
Gross profit	372.7	338.3				
Selling, general and administrative expenses Amortization of intangibles	190.9 13.0	168.6 12.1				
Operating income	168.8	157.6				
Other income (expenses): Interest expense Income from joint venture partnerships Investment income Other, net	(11.9) 15.4 0.4 (0.6)	(8.5) 13.7 0.5 (0.4)				
Earnings before income taxes	172.1	162.9				
Provision for income taxes	70.2	66.3				
Net earnings	\$ 101.9	\$ 96.6				
Basic earnings per common share	\$ 0.82	\$ 0.72				
Diluted earnings per common share	\$ 0.76	\$ 0.67				

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

4

Edgar Filing: LABORATORY CORP OF AMERICA HOLDINGS - Form 10-Q

LABORATORY CORPORATION OF AMERICA HOLDINGS AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS EQUITY (in millions)

(unaudited)

	ommon Stock		Additional Paid-in Capital		Retained Earnings	 Treasury Stock	I	Unearned Restricted Stock mpensation	Con	cumulated Other nprehensive Earnings	Total Shareholders' Equity
BALANCE AT DECEMBER											
31, 2004	\$ 15.1	\$	1,504.1	\$	950.1	\$ (544.2)	\$	(7.5)	\$	81.7	\$ 1,999.3
Comprehensive earnings: Net earnings					96.6						96.6
Other comprehensive earnings:					20.0						70.0
Foreign currency translation											
adjustments										(4.8)	(4.8)
Tax effect of other											
comprehensive loss adjustments										1.9	1.9
1055 adjustments										1.9	
Comprehensive earnings											93.7
Issuance of common stock under employee stock plans	0.1		23.2								23.3
Issuance of restricted stock awards			6.8					(6.8)			
Surrender of restricted stock awards						(7.3)					(7.3)
Cancellation of restricted stock			(0,2)					0.2			
awards			(0.3)					0.3			
Stock compensation Income tax benefit from			0.6					2.5			3.1
stock options exercised			3.9								3.9
Purchase of common stock	 					 (112.0)					(112.0)
BALANCE AT MARCH 31,											
2005	\$ 15.2	\$	1,583.3	\$	1,046.7	\$ (663.5)	\$	(11.5)	\$	78.8	\$ 2,004.0
		• •		_							
BALANCE AT DECEMBER											
31, 2005	\$ 14.8	\$	1,339.7	\$	1,336.3	\$ (888.5)	\$	(6.9)	\$	90.3	\$ 1,885.7
Comprehensive earnings:			·			. ,		. ,			
Net earnings					101.9						101.9
Other comprehensive earnings:											
Foreign currency translation adjustments										(3.0)	(3.0)
Tax effect of other										(3.0)	(5.0)
comprehensive											
loss adjustments										1.1	1.1
Comprehensive earnings											100.0